RXRX remains down by 35% year-to-date and is trading below $5. Thus, the critical question isn’t about a single good ...

Recursion Pharmaceuticals (RXRX) stock rises after J.P. Morgan upgraded the biotech, citing a $1B+ sales potential for the ...

Toward the end of this decade, a choice may face the species that could reshape its interactions with intelligence itself and ...

Former Google CEO Eric Schmidt expressed astonishment at AI's rapid progress, particularly its ability to autonomously generate code, admitting his ow ...

Amazon Q Developer is a useful AI-powered coding assistant with chat, CLI, Model Context Protocol and agent support, and AWS ...

Viewed this way, a definition is a decision mechanism. It distinguishes some elements of the universe from the others. Hence ...

Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

For decades, software developers have been slipping jokes into their work. One of the most enduring, clever, and geekily satisfying inside jokes has been hiding in plain sight: the recursive acronym.

And other pharma news rounded up from around the Pharmalot campus, as told to you by the Pharmalittle newsletter ...

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden ...

Abstract: For classification with small training samples and high dimensionality, feature selection plays an important role in avoiding overfitting problems and improving classification performance.

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.